Has the IACC Finally Embraced Precision Medicine for Autism?

I have been experimenting for the last few days with uploading the EpiphanyASD knowledge base into AI and then asking it to answer questions with this accumulated context in mind.

I am interested in whether this can do something different from simply asking an AI a question about autism.

Instead of treating every question as if it were starting from scratch, can an AI use a large body of material collected over many years—research papers, treatment observations, genetic findings, mechanisms and individual responses—to look at new developments through the particular perspective that has developed on EpiphanyASD?

I am not American, but a major and increasingly controversial topic in the US is the new Interagency Autism Coordinating Committee (IACC) established under HHS Secretary Robert F. Kennedy Jr.

The newly constituted IACC has published its Working Draft Strategic Plan 2026–2028, a huge 336-page document setting out proposed priorities for US autism research, treatment and services.

The original public-comment period was only four days, which produced considerable criticism from autism organisations and other stakeholders. Seven major organisations—including Autism Speaks, the Autism Science Foundation, the Autism Society of America, the National Council on Severe Autism and the Autistic Self Advocacy Network—jointly called for a 90-day extension. The IACC subsequently extended the deadline to August 20, 2026.

So I decided to try something slightly different.

I asked the research copilot running on ChatGPT to read the entire 336-page document and then review it using the EpiphanyASD knowledge base as its background context.

The result was surprisingly interesting.

Rather than simply summarising what the IACC says, I asked it to look for convergence and divergence between the new federal research strategy and the ideas that have emerged from years of research and discussion on EpiphanyASD.

The question was essentially:

Does this new US autism strategy move toward the kind of precision-medicine approach that EpiphanyASD has been exploring for years?

The answer turned out to be yes, in some quite striking ways.

The IACC plan places considerable emphasis on biological heterogeneity, immune and inflammatory biology, folate transport, mitochondrial and redox function, GI and microbiome biology, regression, epilepsy, autonomic dysfunction and—perhaps most importantly—identifying treatment-responsive subgroups rather than assuming that a treatment should work for everyone with an autism diagnosis.

It even explicitly proposes a federal pathway for investigating repurposed medications and for designing clinical trials capable of detecting benefits that might otherwise be hidden in heterogeneous autism populations.

There are also some interesting areas where the EpiphanyASD research agenda goes beyond what is currently included in the IACC plan.

So this is not intended to be a review of whether the new IACC plan is politically good or bad, nor is it an attempt to claim that the IACC has validated treatments discussed on this blog.

Instead, I wanted to see what happens when a large accumulated autism knowledge base is used as the lens through which a major new autism research strategy is examined.

Here is the AI-generated review, with my own comments and editing where appropriate.

I did then take the logical next step and have the Copilot draft an email and pdf attachment with a full list of comments, which I then sent to the IACC. Some of the new members of the IACC are aware of EpiphanyASD already. At least making that 4 day deadline with the Copilot would not be troubling. 10 minutes would be plenty. 

Has the IACC Finally Embraced Precision Medicine for Autism?

An analysis using EpiphanyASD copilot AI of the IACC Strategic Plan 2026–2028

The new IACC plan

The Interagency Autism Coordinating Committee (IACC) has published its Working Draft Strategic Plan 2026–2028 for public review. At 336 pages, it is an enormous document covering autism research, clinical care, services and federal priorities.

I have gone through the therapeutic sections of the document in detail and compared them with the research themes that have repeatedly appeared on EpiphanyASD.

What struck me most was not any particular drug or biological theory. It was the change in the way autism treatment is being conceptualised.

The IACC is increasingly moving away from asking: “Does this treatment work for autism?” and toward: “Does this treatment work for a biologically or clinically identifiable subgroup of autistic people?”

That is a very important change.

Autism may contain many different treatment-responsive subgroups

The new plan explicitly recognises that a treatment can genuinely benefit a subgroup while producing a negative result when tested in an unselected autism population.

The document states that if a drug works for some people but not others, the benefit can be washed out in an all-comers trial. Rather than dismissing such signals, the IACC proposes trials specifically designed to identify and confirm treatment-responsive populations.

This is remarkably consistent with one of the central ideas that has developed on EpiphanyASD.

For years I have argued that autism is unlikely to be a single biological disorder. The behavioural diagnosis may describe a common phenotype while the underlying biology differs considerably between individuals.

One person might have a prominent immune phenotype. Another might have mitochondrial or redox abnormalities. Another might have abnormal folate transport. Another might have significant GI pathology. Another might have epilepsy or abnormal network excitability.

If that is true, then testing a drug across everyone with an autism diagnosis may be a remarkably inefficient way of finding out whether it works.

The 11 therapeutic domains

The plan establishes a series of therapeutic domains:

1. Neurotransmission, neural circuits and neuropsychopharmacology
2. Immune, autoimmune and inflammatory biology
3. Folate metabolism and one-carbon biology
4. Gastrointestinal biology, microbiome function and nutrition
5. Neurodevelopmental regression and functional trajectory
6. Mitochondrial, redox, metabolic and endocrine biology
7. Autonomic dysfunction
8. Sleep and circadian regulation
9. Epilepsy and network excitability
10. Motor function
11. Adaptive trial design and repurposed medications

The important point is that these are not presented as competing explanations for autism. The plan repeatedly emphasises that these biological abnormalities may occur in defined subgroups, and that evidence needs to establish which abnormalities are clinically meaningful and treatment-relevant.

1. Immune and inflammatory biology

The IACC gives immune biology an entire therapeutic domain.

It discusses autoimmune disease, allergic disease, immunodeficiency, inflammatory GI disease, mast-cell disease, post-infectious neuroimmune presentations, neuroinflammation, microglia and astrocytes, cytokines and chemokines, maternal immune biology, autoantibodies and immune-associated regression.

The document does not support the idea that autism is universally an immune disorder. Instead, it says that immune findings may occur in particular clinical subgroups and that the research priority should be identifying those groups.

The important question is no longer simply: “Are cytokines abnormal in autism?”

It is: “Which autistic people have reproducible immune abnormalities, what clinical phenotype do they produce, and do those abnormalities predict treatment response?”

That is a much more useful question.

2. Folate receptor-alpha antibodies and leucovorin

The IACC identifies cerebral folate transport as one of its near-term translational priorities, together with harmonisation of folate receptor-alpha autoantibody assays and confirmatory leucovorin trials in defined subgroups.

The plan distinguishes people with FOLR1 variants and cerebral folate transport deficiency, people with cerebral folate deficiency from other causes, and people with folate receptor-alpha autoantibodies.

The third group remains a candidate subgroup because the assays are not yet sufficiently harmonised and the relationship between antibody status and treatment response requires prospective confirmation.

There is enough evidence to justify a properly designed confirmatory trial, but not enough to say that leucovorin is a treatment for autism generally.

The IACC therefore proposes a sequence of assay harmonisation, subgroup definition, adequately powered multicentre trials, validation of response, and treatment guidance if successful.

This is exactly the sort of progression that precision medicine requires.

3. Mitochondrial and redox biology

The IACC has created a substantial domain covering mitochondrial function, redox biology, metabolism and endocrine physiology.

It discusses oxidative phosphorylation, ATP production, lactate and pyruvate, fatty-acid oxidation, acylcarnitines, carnitine, glutathione, oxidative stress, metabolomics, mitochondrial stress and metabolic vulnerability during physiological stress.

The document distinguishes primary mitochondrial disease from secondary mitochondrial dysfunction or abnormal metabolic stress responses.

This is important because mitochondrial abnormalities should not automatically be interpreted as proof that mitochondria are the cause of someone's autism. They may instead be a susceptibility factor, a consequence of another biological process, a marker of physiological stress, a contributor to particular symptoms, or a predictor of response to a particular intervention.

Determining which of these is true is the research challenge.

NAC and taurine are actually named

There is a particularly interesting detail in this section.

The IACC explicitly lists N-acetylcysteine (NAC) and taurine, alongside L-carnitine, CoQ10, glutathione-directed strategies and riboflavin, as interventions with plausible rationales in selected contexts.

This certainly does not mean that the IACC has concluded that NAC or taurine treat autism. The document says that the evidence is uneven and asks a much more precise question: Which intervention helps which subgroup, based on which biochemical profile, at what dose, and with what measurable improvement?

That is exactly the question that should be asked.

4. Purinergic signalling

One of the more surprising sections concerns purinergic signalling.

The plan discusses extracellular ATP as a danger signal and describes pathways involving P2X and P2Y receptors, P2X7, microglia, calcium signalling, inflammasome activation, CD39, CD73 and adenosine.

It proposes measuring these pathways in defined populations.

This is particularly interesting from an EpiphanyASD perspective because purinergic signalling and the Cell Danger Response have been subjects of discussion on this blog for years.

But the IACC gets the distinction right. Purinergic signalling is presented as an investigational mechanism, not an established explanation for autism and not an immediate indication for antipurinergic treatment.

A biological mechanism can be sufficiently interesting to justify research without being sufficiently proven to justify clinical treatment.

5. Gastrointestinal disease and the microbiome

The IACC has a dedicated domain for Gastrointestinal Biology, Microbiome Function and Nutrition.

The plan recognises that GI problems can manifest as changes in behaviour, sleep or overall functioning and calls for better recognition of ordinary treatable GI disease.

At the same time, it proposes research into mucosal biology, microbial metabolites, enzyme function, microbiome composition, pain, feeding, nutrition, immune-metabolic interactions and diet-responsive interventions.

Importantly, the plan does not recommend treating the microbiome of autistic people indiscriminately. Instead, it proposes precision GI and microbiome trials in defined subgroups.

6. Regression is being treated as a clinical event

Perhaps the most important clinical change in the document concerns regression.

The IACC proposes a national clinical pathway for neurodevelopmental regression and substantial functional loss.

If someone loses previously acquired language, communication, adaptive skills, motor abilities, feeding ability, sleep stability, continence or behavioural regulation, the change should not automatically be attributed to autism. It should trigger appropriate evaluation.

The IACC lists possible contributors including seizures, metabolic problems, mitochondrial vulnerability, immune disease, infection, sleep disruption, GI disease, medication effects, psychiatric deterioration and pain.

Regression is therefore being treated as a clinical phenomenon, not a diagnosis of its cause. There may be multiple types of regression with different biological mechanisms.

The practical consequence is that doctors should investigate the change rather than assume that the underlying autism has simply become more severe.

7. EEG, epilepsy and network excitability

The epilepsy domain goes beyond conventional seizure treatment.

The IACC specifically identifies subclinical epileptiform activity, sleep-potentiated epileptiform discharges, electrical status epilepticus in sleep, altered network excitability and seizure-associated developmental or functional decline.

This is important because some changes that appear behavioural may actually reflect altered brain physiology.

It also reinforces the importance of considering sleep EEG and network activity in appropriate cases rather than assuming that the absence of obvious clinical seizures means that abnormal electrical activity cannot be relevant.

8. Autonomic dysfunction

The IACC identifies dysautonomia, orthostatic intolerance, POTS, abnormal thermoregulation, sweating abnormalities, GI motility abnormalities and abnormal stress-recovery responses.

This is interesting because autonomic physiology provides a possible bridge between several biological systems:

autonomic function ↔ GI function ↔ sleep ↔ immune function ↔ mitochondrial energy metabolism ↔ stress responses.

The plan increasingly treats these systems as interconnected rather than isolated.

9. What about the drugs discussed on EpiphanyASD?

The new IACC plan does not mention every treatment that has been discussed on EpiphanyASD.

For example, searches of the 336-page document did not find bumetanide, NKCC1, CACNA or “calcium channel” under those terms.

That means we should not claim that the IACC has endorsed those particular approaches.

But the methodology of the plan is highly relevant to them.

Bumetanide is a particularly good example. The evidence remains mixed. Some trials and meta-analyses show signals of benefit, while larger or later studies have failed to demonstrate convincing benefit across broad populations.

The obvious question is therefore not necessarily: “Does bumetanide work?”

but: “Is there a subgroup in which bumetanide works substantially better than in the general autism population, and can that subgroup be identified beforehand?”

That is precisely the type of question the IACC's new trial-design framework is intended to address.

The same applies to the calcium-channel hypotheses discussed on EpiphanyASD, including CACNA1C/CACNA2D3 and the possibility of repurposing drugs such as verapamil.

These ideas are not currently represented as priorities in the IACC plan. That is worth saying explicitly. It is one of the areas where EpiphanyASD's research agenda currently goes beyond what appears in this particular federal strategy.

10. The really important section: repurposed drugs and adaptive trials

For me, the most important section of the entire document is Priority Therapeutic Domain 11.

The IACC explicitly recognises the problem of repurposed medications.

Many drugs are already being prescribed off-label. Some have small studies behind them. Some have impressive individual clinical responses. Others fail to replicate.

Yet there is no efficient system for determining whether a credible signal represents a genuine treatment-responsive subgroup.

The IACC proposes a federal pathway for doing precisely this.

The goal is to develop trial designs that can detect treatment effects in heterogeneous populations and provide a route from:

clinical signal → subgroup → trial → evidence → regulatory review.

This is potentially transformative for repurposed drugs.

Why small autism trials can be misleading

Suppose a drug produces 30% major responders, 20% moderate responders and 50% nonresponders.

The average effect may be unimpressive.

A conventional trial could therefore conclude that the drug does not work.

But if the 30% of major responders share a biological characteristic, the correct scientific conclusion might be completely different:

“The treatment doesn't work for everyone—but it may work very well for a particular subgroup.”

The IACC now explicitly recognises this problem.

That is a very important development.

Where EpiphanyASD fits into this

Over the years, EpiphanyASD has accumulated a large collection of observations involving medications, supplements, genetic variants, immune biology, mitochondrial dysfunction, redox biology, GI problems, microbiome changes, EEG abnormalities, regression and metabolic abnormalities.

Some of these observations are strong. Some are weak. Some are anecdotal. Some have subsequently acquired experimental support. Others have not.

They should not all be treated as equivalent evidence.

But the collection has value because it can generate hypotheses.

The challenge has always been converting:

“This unusual person responded dramatically to X”

into:

“What characteristic distinguished this person from the nonresponders?”

That is the step that precision medicine requires.

A new way of looking at the EpiphanyASD database

Rather than asking whether the knowledge base has identified the treatment for autism, it is more useful to ask whether it contains candidate responder phenotypes.

Response to bumetanide → Is there a GABA/ionic-homeostasis subgroup?

Response to leucovorin → Is there a cerebral folate/FRAA subgroup?

NAC response → Is there a redox/oxidative-stress subgroup?

Taurine response → Is there a metabolic/neurotransmission subgroup?

GI-linked behavioural changes → Is there a GI/microbiome/inflammatory subgroup?

Regression after illness → Is there a metabolic, immune or seizure-related subgroup?

EEG abnormalities → Does network excitability predict particular treatment responses?

Particular CACNA variants → Are calcium-channel abnormalities treatment-relevant in a defined genetic subgroup?

Autonomic abnormalities → Do physiological stress-response abnormalities define another subgroup?

These are research questions, not treatment recommendations.

What the IACC plan gets right

I think the strongest aspects of the new plan are fivefold.

1. It recognises heterogeneity. Autism is unlikely to have one biological mechanism.

2. It separates established medical care from experimental biology. An autistic person with epilepsy, inflammatory bowel disease, an endocrine disorder, immune deficiency or another established medical condition should receive ordinary medical care rather than having symptoms attributed automatically to autism.

3. It takes biological subgroups seriously. Immune, mitochondrial, folate, GI and metabolic abnormalities are being considered as potential subgroup characteristics, rather than universal explanations.

4. It recognises the weakness of conventional all-comers trials. A real responder subgroup can disappear statistically when mixed with large numbers of nonresponders.

5. It recognises the potential of repurposed medications. Existing drugs can provide a faster route to treatment than developing completely new molecules—but only if we develop a credible way of determining who benefits.

What is still missing?

The plan is very good at identifying domains, but much harder questions remain.

How do we actually define the subgroups?

A cytokine abnormality is not necessarily a subgroup.

An abnormal metabolite is not necessarily a subgroup.

A genetic variant is not necessarily a treatment biomarker.

A GI symptom is not necessarily a mechanistic subtype.

And an individual response is not proof that the proposed mechanism caused it.

The next step therefore has to be biomarker validation.

The IACC itself repeatedly emphasises assay harmonisation, prospective validation, standardised endpoints and replication before biomarkers are used clinically.

That is exactly right.

The opportunity for autism research

The most encouraging aspect of this document is that it potentially creates a bridge between two worlds that have historically been separated.

On one side we have large-scale academic research and federal funding.

On the other we have clinicians, families and individual treatment experiences.

There are thousands of observations of unusual responses to treatments in autism.

Most will turn out to be noise, placebo effects, regression to the mean, spontaneous fluctuation or coincidence.

But some will not.

The challenge is to develop a scientific system capable of finding the genuine signals.

The IACC's proposed framework—particularly its emphasis on biomarker-defined subgroups, adaptive trials, objective endpoints and repurposed medications—could provide exactly that mechanism.

The big question for EpiphanyASD

After reading all 336 pages, my conclusion is not that the IACC has validated the ideas discussed on EpiphanyASD.

It hasn't.

Nor has it validated NAC, taurine, bumetanide, leucovorin, antipurinergic therapy, mitochondrial treatments, microbiome interventions or any other particular treatment.

What it has done is potentially more important.

It has moved much closer to the research model that EpiphanyASD has been advocating:

Autism is heterogeneous. Identify biologically meaningful subgroups. Find measurable characteristics of those subgroups. Test treatments in the people most likely to respond. Measure meaningful outcomes. Replicate the result.

The convergence is particularly striking in immune biology, folate transport, mitochondrial/redox biology, GI/microbiome function, regression, epilepsy, autonomic dysfunction and purinergic signalling.

And the explicit inclusion of NAC and taurine as examples of mechanism-supported interventions requiring subgroup evidence is notable.

But perhaps the most important development is Domain 11.

For years, one of the biggest problems in autism treatment has been that potentially useful drugs can disappear into the statistical noise of broad clinical trials.

The new IACC plan explicitly acknowledges that problem and proposes developing trials capable of finding treatment-responsive populations.

That is exactly where I believe autism research needs to go next.

Not “What treats autism?”

But:

“Which treatment works for which autistic person—and how can we tell in advance?”

If the IACC can turn that principle into actual biomarker-defined trials, it could represent a genuine change in the way autism treatments are discovered.

And that, rather than any individual drug mentioned in the document, may ultimately be the most important development in this new Strategic Plan.

 

Source note: This article is based on the IACC Working Draft Strategic Plan 2026–2028 and an EpiphanyASD-oriented analysis of its therapeutic domains. It distinguishes research hypotheses from established clinical evidence; the IACC document is a working draft and not an adopted treatment guideline.